Research
Hormonal
Low-carbohydrate diets improve cardiovascular risk markers (triglycerides, HDL, blood sugar, inflammation) and reduce 10-year ASCVD risk scores, despite potential increases in LDL-C in lean individuals.
If you are on a low-carbohydrate diet, expect improvements in triglycerides, HDL, and blood sugar. If your LDL-C rises, discuss with your provider whether it correlates with other risk factors, as overall cardiovascular risk may still decrease.
GoodSupportsHIGH confidence
a substantial body of published work over the past 20 years has documented that low-carbohydrate diets induce favorable changes in many cardiovascular risk markers, including high triglycerides, low HDL-cholesterol, increased small, dense LDL particles, high blood sugar, hyperinsulinemia, hypertension, and chronic inflammation, in addition to reducing stroke risk.
Why this rating
Based on multiple meta-analyses and clinical trials cited by the authors, though the paper is an opinion piece.
Source
Myths and Facts Regarding Low-Carbohydrate Diets
Nina Teicholz et al. · Nutrients · 2025
DOI 10.3390/nu17061047
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Low-carbohydrate diets can induce remission of type 2 diabetes, with clinical trials showing >50% remission rates in some studies.Good
- The 'keto flu' (flu-like symptoms during initial adaptation) can be avoided or alleviated by increasing sodium and mineral intake.Good
- Adherence to a low-carbohydrate diet (defined as ≤130g carbs/day or ≤25% calories) is sustainable long-term and nutritionally adequate, with high adherence rates reported in observational surveys.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →